SCHEMBL6358312

SCHEMBL6358312

COc1ccc(C(=O)CN(C(=O)c2ccccc2)C(C(N)=O)C(C)C)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 2/20 0.45
WNT3A P56704 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
TPMT P51580 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350202 0.92 CTNNB1 (0.46) CTNNB1WNT3ANPC1RAB9ASMN1; SMN2
SCHEMBL6359355 0.90 TP53 (0.42) SMN1; SMN2ALDH1A1TSHRPOLB
SCHEMBL6349745 0.86 TRPM8 (0.54) NPC1RAB9ASMN1; SMN2MEN1ALDH1A1
SCHEMBL6356063 0.86 L3MBTL1 (0.49) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL6350988 0.86 MAPT (0.46) CTNNB1WNT3ASMN1; SMN2MAPTMEN1
SCHEMBL6350864 0.85 TRPM8 (0.47) SMN1; SMN2MAPTMEN1ALDH1A1KMT2A
SCHEMBL6359179 0.85 TRPM8 (0.47) SMN1; SMN2MAPTMEN1ALDH1A1KMT2A
SCHEMBL6347795 0.81 ALDH1A1 (0.43) SMN1; SMN2MEN1ALDH1A1KMT2APOLB
SCHEMBL6351225 0.79 CYP3A4 (0.47) NPC1RAB9AMEN1ALDH1A1KMT2A
SCHEMBL6359454 0.79 CYP3A4 (0.47) NPC1RAB9AMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 CTNNB1 1529/4885WNT3A 1891/4885NPC1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.